市場調査レポート

商品コード

1396987

マルチプレックス診断市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023年～2032年

Multiplexed Diagnostics Market By Product Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年10月31日 | 発行: Allied Market Research

| ページ情報: 英文 425 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 558,990円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 897,203円

レポートPDFをご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,503,168円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

マルチプレックス診断の世界市場規模は2022年に107億米ドルで、2032年には415億米ドルに達し、2023年から2032年までのCAGRは14.5%で成長すると予測されています。

多重化とは、1つの診断検査で複数のバイオマーカーを同時に検出または同定するプロセスであり、複数の異なる種類の疾患に対して有用です。例えば、心血管疾患患者を対象としたファーマコゲノミクス研究では、多型の存在が様々な薬剤に対する患者の反応性に影響することが示されています。したがって、関連バイオマーカーの多重検出は、心血管疾患の病態生理に関する洞察を提供するだけでなく、最も効率的な治療法の指針としても役立ちます。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 個別化医療に対する需要の高まり
  - 慢性疾患の増加
  - 多重化診断製品の技術的進歩
- 抑制要因
  - 多重化診断に伴う高コスト
- 機会
  - 多重化診断薬の用途拡大

第4章マルチプレックス診断市場：製品タイプ別

概要
装置・付属品
キット・試薬

第5章マルチプレックス診断市場：用途別

概要
感染症
腫瘍学
自己免疫疾患
心臓疾患
アレルギー
その他

第6章マルチプレックス診断市場：エンドユーザー別

概要
病院
診断センター
その他

第7章マルチプレックス診断市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Co-Diagnostics, Inc.
F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
BioMerieux SA
Illumina Inc.
Hologic Inc.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc
Siemens Healthineers AG
Diasorin S.p.A.

図表

LIST OF TABLES

TABLE 01. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 06. MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. MULTIPLEXED DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. UK MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. UK MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 65. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. CO-DIAGNOSTICS, INC.: KEY EXECUTIVES
TABLE 90. CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT
TABLE 91. CO-DIAGNOSTICS, INC.: PRODUCT SEGMENTS
TABLE 92. CO-DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 94. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 96. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 98. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 99. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 100. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 101. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 102. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 103. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 104. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 105. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 106. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 107. BIOMERIEUX SA: KEY STRATERGIES
TABLE 108. ILLUMINA INC.: KEY EXECUTIVES
TABLE 109. ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 110. ILLUMINA INC.: PRODUCT SEGMENTS
TABLE 111. ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 112. HOLOGIC INC.: KEY EXECUTIVES
TABLE 113. HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 114. HOLOGIC INC.: PRODUCT SEGMENTS
TABLE 115. HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 116. HOLOGIC INC.: KEY STRATERGIES
TABLE 117. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 118. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 119. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 120. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 121. BIO-RAD LABORATORIES INC: KEY EXECUTIVES
TABLE 122. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 123. BIO-RAD LABORATORIES INC: PRODUCT SEGMENTS
TABLE 124. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 125. BIO-RAD LABORATORIES INC: KEY STRATERGIES
TABLE 126. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 127. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 128. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS
TABLE 129. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 130. DIASORIN S.P.A.: KEY EXECUTIVES
TABLE 131. DIASORIN S.P.A.: COMPANY SNAPSHOT
TABLE 132. DIASORIN S.P.A.: PRODUCT SEGMENTS
TABLE 133. DIASORIN S.P.A.: PRODUCT PORTFOLIO
TABLE 134. DIASORIN S.P.A.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF MULTIPLEXED DIAGNOSTICS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN MULTIPLEXED DIAGNOSTICS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN MULTIPLEXED DIAGNOSTICS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. MULTIPLEXED DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 26. U.S. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. CANADA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. UK MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. ITALY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. CHINA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 37. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 38. INDIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 41. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 42. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: MULTIPLEXED DIAGNOSTICS MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2022
FIGURE 52. CO-DIAGNOSTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 56. AGILENT TECHNOLOGIES, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 57. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 61. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 62. ILLUMINA INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. ILLUMINA INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. ILLUMINA INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 69. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 71. BIO-RAD LABORATORIES INC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 72. BIO-RAD LABORATORIES INC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 73. BIO-RAD LABORATORIES INC: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 74. SIEMENS HEALTHINEERS AG: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 75. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 76. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 77. DIASORIN S.P.A.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 78. DIASORIN S.P.A.: REVENUE SHARE BY REGION, 2021 (%)

Product Code: A15440

The global multiplexed diagnostics market was valued at $10.7 billion in 2022, and is projected to reach $41.5 billion by 2032, growing at a CAGR of 14.5% from 2023 to 2032.Multiplexing is the process of simultaneously detecting or identifying multiple biomarkers in a single diagnostic test, which can be valuable for several different types of diseases. For instance, pharmacogenomic studies in patients with cardiovascular disease have indicated that the presence of polymorphisms affects response of a patient to various drugs. The multiplex detection of relevant biomarkers, hence, not only provides insight into the pathophysiology of cardiovascular disease, but also serves as a guide for the most efficient treatment option.

In addition, multiplex tests simultaneously analyze samples for multiple pathogens. Currently, available multiplex tests, including those from the life sciences company Thermo Fisher Scientific, leverage PCR techniques to selectively amplify genes specific to each virus of interest. For SARS-CoV-2, the test might amplify genes that code for the envelope protein (E gene) of the virus or the nucleocapsid protein (N gene). Targets may include virus specific matrix proteins as well as nucleocapsid proteins for Influenza A, B, and Respiratory syncytial virus (RSV), polymerase chain reaction (PCR).

Major factors that drive the growth of the global multiplexed diagnostics market include an increase in need for automated equipment and varied analytical methodologies, increase in incidence of disease outbreaks such as coronavirus and Ebola virus, and surge in technological innovations in assay design, detection methods, and data analysis techniques.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders are the major factors that increase the demand for multiplexed diagnostics tests kits and instruments and hence propel the growth of the market.

In addition, the increase in the number of key market players and the strategies they adopt for the development of technologically advanced multiplexed diagnostics products are the major factors that boost the growth of the multiplexed diagnostics market. For instance, in January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. Integrating Dako Omnis (auto-staining instrument) of Agilent and PhenoImager HT (imaging platform) of Akoya for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays create a singular end-to-end commercial workflow, including reagents, staining, imaging, and analysis.

However, the high cost associated with multiplexed diagnostic assay, and lack of skilled professionals to operate diagnostic tools and conduct multiplexed diagnostic assay restrain the growth of the multiplexed diagnostics market. On the contrary, the surge in the demand for novel home health monitoring systems such as increase in demand for xPOCT devices, which ensure the quality and performance requirements of in vitro diagnostics, performed in a short period by non-experts and increased use of personalized medicine are expected to provide additional opportunities for the multiplexed diagnostics market to grow during the forecast period.

The multiplexed diagnostics market is segmented into product type, application, end user, and region. On the basis of product type, the market is bifurcated into instruments & accessories and kits & reagents. On the basis of application, it is segregated into infectious disease, oncology, autoimmune disease, cardiac disease, allergies, and others. On the basis of end user, it is segmented into hospitals, diagnostic centers, and others. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Co-Diagnostics, Inc. Agilent Technologies, Inc., bioMerieux SA, Illumina Inc., Hologic, Inc. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and DiaSorin S.p.A. The key players such as bioMerieux SA, Hologic, Inc. F. Hoffmann-La Roche Ltd., Agilent Technologies Inc, Bio-Rad Laboratories and DiaSorin S.p.A have adopted product launch, product approval, acquisition, and partnership as major developmental strategies to improve the product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the multiplexed diagnostics market analysis from 2022 to 2032 to identify the prevailing multiplexed diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the multiplexed diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global multiplexed diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

New Product Development/ Product Matrix of Key Players
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product Type

Instruments and Accessories
Kits and Reagents

By Application

Infectious Disease
Oncology
Autoimmune Diseases
Cardiac Diseases
Allergies
Others

By End User

Hospitals
Diagnostic Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Agilent Technologies, Inc.
Hologic Inc.
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
BioMerieux SA
F. Hoffmann-La Roche Ltd.
Diasorin S.p.A.
Illumina Inc.
Bio-Rad Laboratories Inc
Co-Diagnostics, Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Growth in demand for personalized medicine
  - 3.4.1.2. Rise in prevalence of chronic disease
  - 3.4.1.3. Technological advancements in multiplexed diagnostics products
- 3.4.2. Restraints
  - 3.4.2.1. High cost associated with multiplexed diagnostics
- 3.4.3. Opportunities
  - 3.4.3.1. Expansion of applications of multiplexed diagnostics

CHAPTER 4: MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Instruments and Accessories
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Kits and Reagents
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Infectious Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Oncology
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Autoimmune Diseases
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Cardiac Diseases
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Allergies
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Others
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country

CHAPTER 6: MULTIPLEXED DIAGNOSTICS MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic Centers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MULTIPLEXED DIAGNOSTICS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Product Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Product Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Product Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Product Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Product Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Product Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Product Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Product Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Product Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Product Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Product Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Market size and forecast, by Product Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. India
  - 7.4.5.4.1. Market size and forecast, by Product Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Product Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Product Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Product Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Product Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Product Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Product Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Co-Diagnostics, Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. F. Hoffmann-La Roche Ltd.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Agilent Technologies, Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. BioMerieux SA
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Illumina Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Hologic Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Thermo Fisher Scientific Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Bio-Rad Laboratories Inc
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Siemens Healthineers AG
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Diasorin S.p.A.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

マルチプレックス診断市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023年～2032年

Multiplexed Diagnostics Market By Product Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章マルチプレックス診断市場：製品タイプ別

第5章マルチプレックス診断市場：用途別

第6章マルチプレックス診断市場：エンドユーザー別

第7章マルチプレックス診断市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product Type

By Application

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE

CHAPTER 5: MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION

CHAPTER 6: MULTIPLEXED DIAGNOSTICS MARKET, BY END USER

CHAPTER 7: MULTIPLEXED DIAGNOSTICS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

マルチプレックス診断市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023年～2032年

Multiplexed Diagnostics Market By Product Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 マルチプレックス診断市場：製品タイプ別

第5章 マルチプレックス診断市場：用途別

第6章 マルチプレックス診断市場：エンドユーザー別

第7章 マルチプレックス診断市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product Type

By Application

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE

CHAPTER 5: MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION

CHAPTER 6: MULTIPLEXED DIAGNOSTICS MARKET, BY END USER

CHAPTER 7: MULTIPLEXED DIAGNOSTICS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章マルチプレックス診断市場：製品タイプ別

第5章マルチプレックス診断市場：用途別

第6章マルチプレックス診断市場：エンドユーザー別

第7章マルチプレックス診断市場：地域別

第8章競争情勢

第9章企業プロファイル